21-hydroxylase deficiency primary prevention: Difference between revisions
Jump to navigation
Jump to search
(Created page with "__NOTOC__ {{Congenital adrenal hyperplasia}} Please help WikiDoc by adding more content here. It's easy! Click here to learn about editing. {...") |
Aditya Ganti (talk | contribs) |
||
| (16 intermediate revisions by 6 users not shown) | |||
| Line 1: | Line 1: | ||
__NOTOC__ | __NOTOC__ | ||
{{ | {{21-hydroxylase deficiency}} | ||
{{CMG}}; {{AE}} {{MJ}} | |||
{{CMG}} | |||
==Overview== | ==Overview== | ||
[[Pre-natal]] diagnosis of 21-hydroxylase deficiency is established to [[Prevention (medical)|prevent]] complications of the disease in future life and treated with [[pre-natal]] [[dexamethasone]]. | |||
==Primary Prevention== | ==Primary Prevention== | ||
* | * [[Pre-natal]] diagnosis of 21-hydroxylase deficiency in patients with positive [[family history]] is established to prevent complications in future. A positive diagnosis is treated with [[prenatal]] [[dexamethasone]]. | ||
* The tests available for making a [[pre-natal]] diagnosis of 21-hydroxylase deficiency include: | |||
** [[Amniotic fluid]] testing | |||
** [[Oligonucleotide]] hybridization of [[deoxyribonucleic acid]] ([[DNA]]) obtained from [[chorionic villus sampling]] utilizes [[fetal]] [[DNA]] extracted from maternal blood through non-invasive methods.<ref name="pmid27378492">{{cite journal |vauthors=Kazmi D, Bailey J, Yau M, Abu-Amer W, Kumar A, Low M, Yuen T |title=New developments in prenatal diagnosis of congenital adrenal hyperplasia |journal=J. Steroid Biochem. Mol. Biol. |volume=165 |issue=Pt A |pages=121–123 |year=2017 |pmid=27378492 |doi=10.1016/j.jsbmb.2016.06.016 |url=}}</ref> | |||
== References == | ==References== | ||
{{Reflist|2}} | {{Reflist|2}} | ||
{{WH}} | |||
{{ | {{WS}} | ||
{{ | |||
[[Category:Disease]] | [[Category:Disease]] | ||
[[Category:Pediatrics]] | [[Category:Pediatrics]] | ||
| Line 24: | Line 20: | ||
[[Category:Genetic disorders]] | [[Category:Genetic disorders]] | ||
[[Category:Intersexuality]] | [[Category:Intersexuality]] | ||
[[Category:Medicine]] | |||
[[Category:Up-To-Date]] | |||
Latest revision as of 15:29, 24 July 2020
|
21-hydroxylase deficiency Microchapters |
|
Differentiating 21-Hydroxylase Deficiency from other Diseases |
|
Diagnosis |
|
Treatment |
|
Case Studies |
|
21-hydroxylase deficiency primary prevention On the Web |
|
American Roentgen Ray Society Images of 21-hydroxylase deficiency primary prevention |
|
Risk calculators and risk factors for 21-hydroxylase deficiency primary prevention |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Mehrian Jafarizade, M.D [2]
Overview
Pre-natal diagnosis of 21-hydroxylase deficiency is established to prevent complications of the disease in future life and treated with pre-natal dexamethasone.
Primary Prevention
- Pre-natal diagnosis of 21-hydroxylase deficiency in patients with positive family history is established to prevent complications in future. A positive diagnosis is treated with prenatal dexamethasone.
- The tests available for making a pre-natal diagnosis of 21-hydroxylase deficiency include:
- Amniotic fluid testing
- Oligonucleotide hybridization of deoxyribonucleic acid (DNA) obtained from chorionic villus sampling utilizes fetal DNA extracted from maternal blood through non-invasive methods.[1]
References
- ↑ Kazmi D, Bailey J, Yau M, Abu-Amer W, Kumar A, Low M, Yuen T (2017). "New developments in prenatal diagnosis of congenital adrenal hyperplasia". J. Steroid Biochem. Mol. Biol. 165 (Pt A): 121–123. doi:10.1016/j.jsbmb.2016.06.016. PMID 27378492.